DCGI panel backs nod for India’s 1st flu shot from Cadila
The committee met in the last week of November and deliberated on the phase-3 clinical trials report submitted by the firm.
NEW DELHI : The Subject Expert Committee of the Drugs Controller General of India (DCGI) has recommended granting manufacturing approval to Cadila Pharmaceutical for India’s first indigenously developed seasonal flu vaccine. However, the final nod can be given only by the regulator.
Login to enjoy exclusive benefits!
- Unlocked premium articles
- Personalized news
- Market Watchlist
- Insightful Newsletters & more